Age-Specific Incidence Data Indicate Four Mutations Are Required for Human Testicular Cancers by Brody, James P.
Age-Specific Incidence Data Indicate Four Mutations Are
Required for Human Testicular Cancers
James P. Brody*
Department of Biomedical Engineering, Center for Complex Biological Systems, University of California Irvine, Irvine, California, United States of America
Abstract
Normal human cells require a series of genetic alterations to undergo malignant transformation. Direct sequencing of
human tumors has identified hundreds of mutations in tumors, but many of these are thought to be unnecessary and a
result of, rather than a cause of, the tumor. The exact number of mutations to transform a normal human cell into a tumor
cell is unknown. Here I show that male gonadal germ cell tumors, the most common form of testicular cancers, occur after
four mutations. I infer this by constructing a mathematical model based upon the multi-hit hypothesis and comparing it to
the age-specific incidence data. This result is consistent with the multi-hit hypothesis, and implies that these cancers are
genetically or epigenetically predetermined at birth or an early age.
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Introduction
Tumors originate from a single cell after the cell accumulates a
series of mutations [1–6], according to the multi-hit model of
cancer [2,3]. These mutations can include many different types of
alterations to the DNA including methylation, single base
substitutions, and duplications or deletions of chromosomes. The
exact number of mutations required to transform a normal human
cell into a tumor cell is unknown [7].
Direct DNA sequencing of tumors has established an upper
limit on the number of mutations required to transform a cell.
Sequencing of breast and colorectal cancers identified about 80
mutations in a typical tumor [8]. Further statistical analysis
suggested that less than 15 of those 80 are necessary [8]. A second
experiment sequenced 623 known cancer-related genes in a set of
188 lung adenocarcinomas showing more than 1000 somatic
mutations. Further analysis identified 26 genes that were
concluded to be involved in carcinogenesis [9].
A lower limit on the number of mutations to transform a normal
cell has been established in the laboratory. A human tumor cell was
synthesized from normal human cells (both epithelial and fibroblast
cells) by altering the expression of only three genes, which effected
four biochemical pathways [6,10]. This tumor cell displayed the
classic characteristics of a human tumor cell: anchorage-indepen-
dent growth and formation of tumors in nude mice.
It is widely believed that colon tumors require four to six
mutations [11]. This is based upon comparing the Armitage and
Doll equation, I~atr{1 [12], to age-specific incidence data. But
many problems exist with this [13]: it fails to describe the data at
older ages; it increases without any upper limits; and it does not
incorporate clonal expansion.
Testicular gonadal germ cell cancers differ from other solid
tumors in a number of ways. First, the incidence of gonadal germ
cell tumors is highest at about 30 years of age and declines to just a
handful of cases diagnosed in men in their 70’s. In comparison, the
incidence of many other solid tumors increases with age. Second,
combination chemotherapy is particularly effective against testic-
ular gonadal germ cell tumors as compared to other solid tumors.
Finally, most solid tumors originate in somatic cells, while most
testicular cancers arise in germ cells.
The cause of testicular gonadal germ cell tumors is not known
[14,15]. No known environmental factors affect its development
[16]. A family link exists, stronger in brothers than father and sons
[17]. Testicular cancers showed the third highest heritability, but
most cases are sporadic [18]. Age standardized rates of testicular
cancer have increased over the past few decades in the United
States [19] and in other parts of the world [20].
The strongest association of testicular cancer with any other
medical conditions is with cryptorchidism, where the testicles do
not descend into the scrotum at birth. About 5 to 10% of those
who develop testicular cancer had undescended testicles at birth,
compared to about 2 to 5% in the general population [21]. It is not
known whether cryptorchidism causes testicular cancers or
whether both are caused by a common factor.
Two hypotheses exist for the origin of testicular cancers. The
first suggests that testicular cancers are determined in utero or at an
early age [22,23]. A second is that environmental exposure to
carcinogens throughout ones lifetime leads to the development of a
tumor, while genetics modifies this environmental risk [24].
Although this second hypothesis is widely believed, little evidence
exists that environmental mutagens cause any of the point
mutations observed in human cancers [25].
Tests of these hypotheses are mixed. A retrospective study of
Swedish males found that those who underwent surgery before the
age of 13 to correct undescended testicles had a slightly lower risk
of developing testicular cancer than those who did not undergo
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predetermined at birth. However, a similar study containing
almost twice as many subjects in Denmark found no significant
change in the incidence of testicular cancer after surgery for
undescended testicles [26].
Two genome wide association studies identified several
mutations that predispose to the development of testicular tumors
[27,28]. These mutations are located in two genes, KITLG and
SPRY4, that are known to play a role in testicular development.
The estimated per allele odds ratio for these are among the highest
found for any genome wide association study of a cancer [29].
Previously, others have sought to understand the age-specific
incidence of cancers with different approaches. Including using a
Weibull distribution for lung cancer [30], analyzing the age-
specific acceleration of cancers [31,32], modifying the Armitage
Doll equation directly with a damping term [33–35], and using a
multistage model with age-dependent behavior to estimate the
number of mutations required to develop breast cancer [36]. An
analysis of Danish and Norwegian cancer registries suggests that
testicular cancer age-specific incidence data are best modeled with
a frailty effect, where a portion of the population is non-susceptible
to developing the cancer [37].
The objective of this paper is to determine how many mutations
are required to develop testicular cancer. The approach is to
compare the expected age-specific incidence, based upon the
multi-hit model, with the measured age-specific incidence for
testicular cancers.
Results
The age-specific incidence for testicular cancers is accurately
described by Equation (1) with four mutations. Figure 1 shows a
comparison between Equation (1) and data for all eight years. This
also implies that testicular cancers develop from a single
progenitor cell. Table 1 shows the parameters and error estimates,
and p-value for individual years.
Figure 2 compares the best fits for models with three, four, and
five mutations. The model with four mutations was the best fit.
Three mutations provided a slightly worse fit in the 15–20 and 65–
75 age range, while five mutations provided a much worse fit in
the range of 10–25 years, but was indistinguishable from 4
mutations in the 50–75 age range.
I measured the probability of advancing to the next stage at
(1{0:853~)0:147 per year. This measures only the probability of
a mutation that would advance the precancerous tissue another
step towards cancer, and is not directly comparable to measured
mutation rates. Human germ line mutations vary across the
genome by orders of magnitude [38]; a single mutation rate
cannot accurately characterize the process.
Discussion
The approach presented here implicitly assumes that the
probability of advancing to the next stage, which could be
associated with a mutation rate, is constant. Complexity could be
added to the model by modifying this assumption. At least two
different mechanisms could modify the mutation rate in a pre
cancerous tissue. First, the mutator phenotype hypothesis suggests
that one of the first mutations on the path to a tumor must result in
a higher mutation rate [39]. Second, the process of clonal
expansion can expand the pool of cells at one stage, increasing the
probability of advancing to the next stage [40–42]. Since the
simplest assumption, a constant probability of advancing, was
sufficient in this case, I did not extend the model to include a
changing probability rate.
The mutations are most likely chromosomal additions or
deletions, not single base alterations. Cytogenetic studies of
seminoma and non-seminoma testicular cancers have shown
consistent alterations to several chromosomes. In particular,
amplification of a region of chromosome 12p containing several
known genes is often present [43].
Although four mutations are required for the development of
testicular cancers, these mutations may alter more than four genes
and biochemical pathways. In addition, other mutations that are
not rate limiting may occur. Non rate limiting mutations would
not alter the age-specific incidence data.
Figure 1. This is a comparison between the observed (SEER-17,
2000–2007) age-specific incidence for testicular cancers and
that predicted by the multi-hit model with four mutations. The
black circles represent the measured incidence, the error bars are 95%
confidence intervals, and the green solid line represents the incidence
predicted by the multi-hit model with four mutations.
doi:10.1371/journal.pone.0025978.g001
Table 1. The best estimate of the parameters A (number of
men per 100,000 who will ultimately develop testicular cancer
in their lifetime) and q (the probability per year that no
mutation occurs).
Year P-value A q
2000 0.017 387 0.856
2001 0.043 381 0.856
2002 0.059 379 0.855
2003 0.497 370 0.854
2004 0.316 387 0.851
2005 0.004 381 0.851
2006 0.722 382 0.854
2007 0.350 376 0.846
0.2606 380(+5) 0.853(+0.003)
I tested the hypothesis that the testicular cancer age-specific incidence data
were derived from Equation 1. To obtain the best estimate of the parameters in
Equation 1, I performed a least squares fit of Equation 1 to the age-specific
incidence data for eight consecutive years (2000–2007). This table lists the best
estimate of the parameters A (number of men per 100,000 who will ultimately
develop testicular cancer in their lifetime) and q (the probability per year that
no mutation occurs). It also lists the p-value, the probability that the hypothesis
should not be rejected.
doi:10.1371/journal.pone.0025978.t001
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significant long term change in the rate of testicular cancers. The
SEER-9 data show that the age-adjusted testicular cancer rate has
increased by about 7% per year from 1973 to 2008. The standard
way for dealing with temporal variation in cancer rates is to first
analyze age models, then age plus drift, then age-period and/or
age-cohort, and finally age-period-cohort models [44,45]. Each
addition of complexity requires additional parameters and reduces
the number of degrees of freedom. Since the age only model
provided a good fit to the data, further complexity was avoided.
However, future work on the age-specific incidence of testicular
cancer should explore whether these more complex models
provide alternative solutions.
Additional complexity to the model could be added in different
ways. To account for inherited mutations, the model could consist
of two independent terms similar to Equation (1). The first term
would require r{1 mutations and the second term would require
r mutations. To account for multiple pathways by which testicular
cancer could develop, the model could be extended by adding a
second term with independent parameters from the first. Neither
of these additions are necessary, but the data does not exclude the
possibility of these more complex processes.
The agreement between the age-specific incidence data and
Equation (1) implies that testicular cancers have a single potential
progenitor cell. This contrasts with most other types of solid
tumors which are thought to have many, many potential
progenitor cells.
The age-specific incidence data implies that testicular cancers
are pre-determined before the age of 10 and possibly at birth
either through genetic or epigenetic [46] predisposition. This data
is inconsistent with a hypothesis where exposure to environmental
carcinogens in mature men lead to the development of a testicular
tumor.
Methods
The multi-hit model describes a series of independent Bernoulli
trials. A random number is drawn between zero and one. If the
number is less than q, no mutation occurs; if greater than q,a
mutation occurs. The process is repeated periodically. When r
mutations have occurred, a tumor begins to develop. The tumor
grows, through clonal expansion, over an additional time t until it
is detected as a cancer. The time t might also be related to normal
growth and development. This process occurs in a fraction of the
population, A, that lies somewhere between 0 and 100%.
Under these assumptions, the probability distribution for the
age at which testicular cancer is diagnosed should be given by the
solution to the series of independent Bernoulli trials, the negative
binomial distribution [47]
p(t)~A
((t{t){1)!
((t{t){r)!(r{1)!
(1{q)
rq((t{t){r): ð1Þ
The age-specific incidence measures the hazard function, which is
related to Equation (1) by dividing by the ratio of the total
population to the at-risk population. Males who have been
previously diagnosed with testicular cancer are removed from the
total population to produce the at-risk population. The effect of
this is at most 0:3% on p(t) and can be ignored in this case since it
is overwhelmed by the predominant sampling error.
One assumption in the derivation of Equation (1) is that a single
progenitor cell exists in the tissue. If many progenitor cells exist, as
is thought to occur in most tissues, then cancer is diagnosed when
the first of these many cells develops into a tumor. In this case, the
first order statistic, or distribution of the minimum, of Equation (1)
is the proper equation to compare to the age-specific incidence
data. This would follow a Weibull distribution [30,48].
I tested the hypothesis that the age-specific incidence data on
testicular germ cell tumors is accurately described by Equation (1).
I performed a least squares fit to determine the parameters of the
equation for all eight years in the dataset. Then, I calculated the
reduced chi-squared value and the associated p-value, given the
number of degrees of freedom, 53. The p-value, shown in Table 1,
indicates the probability that the hypothesis should not be rejected.
In the United States, the Surveillance, Epidemiology, and End
Results (SEER) Program of the National Cancer Institute (NCI)
collects data on cancer cases. It is considered the gold-standard for
data quality for cancer registries. It collects data from 17 different
geographic regions that encompass just over 26% of the
Figure 2. This figure compares the best fit models for three, four, and five mutations. To emphasize the differences, only regions before
the age of 25 and after the age of 50 are shown. All three models show close fit to the data between 25 and 50 years of age. The models with four
mutations and five mutations are identical after the age of 50.
doi:10.1371/journal.pone.0025978.g002
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US Census data on the population, as a function of age, in the
these 17 geographic areas to calculate the age-specific incidence.
I obtained testicular germ cell tumor age-specific incidence data
using SEER*Stat (version 6.6.2) [50]. SEER*Stat allows one to
easily query the SEER case files. I queried the database published
in November 2009, the SEER 17 incidence database with single
ages to 85z [49]. This was the most recent available. I selected all
reported tumors that were in males, located in the testis, and
classified as germ cell or trophoblastic tumors or neoplasms of
gonads, totaling 16,291 cases. I excluded testicular cancers
diagnosed before the age of 13, because they were probably due
to a different mechanism, 88 cases were excluded. Those
diagnosed before the age of four are probably teratoma-yolk sac
tumors [43]. These account for only a small fraction (0.5%) of all
testicular cancers. (From 2000–2007, the SEER-17 registries
recorded 88 testicular germ cell cancers in patients under 13, 72 of
these cancers were diagnosed in the first 36 months of life.)
I compared Equation (1) to age-specific incidence data collected
by the SEER-17 cancer registries from 2000–2007 on the
incidence of testicular cancers, both seminomas and non-
seminomas. I compared these equations with the data from ages
13 to 70 years old and with the number of mutations, r, ranging
from three to five. This comparison was made by minimizing the
reduced chi-squared value [51] using the Generalized Reduced
Gradient algorithm. This algorithm is suitable for minimizing non-
linear functions. I used multiple starting points to ensure that the
solution given was the global minimum and not a local minima.
I calculated error estimates by measuring the parameters A and
q for eight individual years (2000–2007) and taking the standard
deviation of these eight values. Uncertainty in the parameter, r,
which represents the number of mutations required to develop a
tumor, was measured by comparing models for three, four, and
five mutations, as shown in Table 2.
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